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Objective: The aim of this study was to calculate the 
range of absorbed doses that could potentially be 
delivered by a variety of radiopharmaceuticals and 
typical fixed administered activities used for bone 
pain palliation in a cohort of patients with metastatic 
castration-resistant  prostate cancer  (mCRPC). The 
methodology for the extrapolation of the biodistri-
bution, pharmacokinetics and absorbed doses from 
a given to an alternative radiopharmaceutical is 
presented.
Methods: Sequential single photon  emission CT 
images from 22 patients treated with 5 GBq of 186Re-
HEDP were used to extrapolate the time–activity 
curves for various radiopharmaceuticals. Cumulated 
activity distributions for the delivered and extrapo-
lated treatment plans were converted into absorbed 
dose distributions using the convolution dosimetry 
method. The lesion absorbed doses obtained for the 
different treatments were compared using the patient 
population distributions and cumulative dose–volume 
histograms.
Results: The median lesion absorbed doses across the 
patient cohort ranged from 2.7 Gy (range: 0.6–11.8 Gy) for 
1100 MBq of 166Ho-DOTMP to 21.8 Gy (range: 4.5–117.6 Gy) 
for 150 MBq of 89Sr-dichloride. 32P-Na3PO4, 
153Sm-EDTMP, 
166Ho-DOTMP, 177Lu-EDTMP and 188Re-HEDP would have 
delivered 41, 32, 85, 20 and 64% lower absorbed doses, for 
the typical administered activities as compared to 186Re-
HEDP, respectively, whilst 89Sr-dichloride would have 
delivered 25% higher absorbed doses.
Conclusion: For the patient cohort studied, a wide range 
of absorbed doses would have been delivered for typical 
administration protocols in mCRPC. The methodology 
presented has potential use for emerging theragnostic 
agents.
Advances in knowledge: The same patient cohort can 
receive a range of lesion absorbed doses from typical 
molecular radiotherapy treatments for patients with 
metastatic prostate cancer, highlighting the need to 
establish absorbed dose response relationships and to 
treat patients according to absorbed dose instead of 
using fixed administered activities.
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intRODuCtiOn
Prostate cancer is the most common cancer in males in the 
UK (2014), accounting for 26% of all new cancer diagnoses 
in males.1 Androgen deprivation therapy is the primary 
treatment for patients with metastatic prostate cancer, 
although the disease eventually progresses to the castra-
tion-resistant stage. Effective treatment is primarily palli-
ative and disseminated bone metastases are often managed 
with molecular radiotherapy  (MRT)  towards the latter 
stages of the disease. A wide range of radiopharmaceuti-
cals are available for bone pain palliation in patients with 
metastatic castration-resistant prostate cancer (mCRPC). 
These include bone-seeking calcium-analogues such as 
89Sr-dichloride and 223Ra-dichloride and phosphates such 
as 153Sm-EDTMP, 186Re-HEDP and 188Re-HEDP.2,3 More 
recently, newly emerging radiolabelled prostate-specific 
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Table 1. List of radiopharmaceuticals, physical and effective half-lives, bone uptake and administered activity for typical molecular 
radiotherapy treatments of mCRPC
Radiopharm. Physical half-life (d) Effective half-life (d) Bone uptake (%IA) Administered activity (MBq)
32P-Na₃PO₄ 14.268 13 20 450
89Sr-dichloride 50.563 29 65 150
153Sm-EDTMP 1.9379 1.6 70 37 (kg–1)
166Ho-DOTMP 1.1177 0.93 30 1100
177Lu-EDTMP 6.647 3.9 60 37 (kg–1)
188Re-HEDP 0.78500 0.66 30 3300
membrane antigen (PSMA)-binding radiopharmaceuticals show 
promise in treating bone and soft-tissue metastases.4–6
The efficacy of MRT relies on the delivery of high absorbed doses to 
the metastatic soft-tissue whilst minimizing the damage to healthy 
tissues. The red marrow is the major organ at risk for bone treat-
ments and can, therefore limit the administered activity. Several 
models are available for dosimetry calculations in the normal skel-
eton,7–10 whilst lesion dosimetry is performed using sphere models 
or voxel dosimetry where the activity is assumed to be uniformly 
distributed through the volume.  Accurate lesion dosimetry calcu-
lations require the determination of the activity distribution using 
sequential quantitative imaging. However, imaging of small bone 
metastatic lesions remains a challenge due to the limited spatial 
resolution of present clinical imaging systems and associated partial 
volume effects. A wide range of tumour absorbed doses are reported 
in the literature for MRT in mCRPC: 33 mGy MBq–1;11 2.1 mGy  
MBq–1;12 and 3.7 mGy MBq–1;13 for 186Re-HEDP; 3.8 Gy MBq–1 
for 188Re-HEDP;14 37 mGy  MBq–1 for 89Sr-dichloride;15 in 
excess of 62 mGy  MBq–1 for 131I-MIP-1095 4.0 mGy  MBq–1;16 
and 4.4 mGy  MBq–1;17 for 153Sm-EDTMP; 3.3 mGy  MBq–1 for 
177Lu-PSMA-DOTA-J591;5 and 13.1 mGy  MBq–1 for 177Lu-DK-
FZ-PSMA-617.18 These radiopharmaceuticals exhibit different 
physiological effects and the absorbed doses reported have been 
calculated using different methodologies. These make comparisons 
within patients receiving the same treatment and between treat-
ments challenging.
The aim of this study was to demonstrate the wide range of 
absorbed doses that can be delivered from typical administered 
activities of various MRT treatments used to treat mCRPC and 
to present the methodology to extrapolate the absorbed doses 
delivered from any chosen radiopharmaceutical to those that 
would be delivered if another radiopharmaceutical was adminis-
tered. Patient-specific imaging from a cohort of patients treated 
with 186Re-HEDP were used to extrapolate the absorbed doses 
that would have been delivered if the same patients were treated 
with various treatments used for bone pain palliation.
MethODs AnD MAteRiAls
Clinical data
Available Phase II clinical trial data from a cohort of 22 patients 
treated with a median 5020 MBq of 186Re-HEDP and autolo-
gous peripheral blood stem cell transplantation were included. 
Sequential single photon emission CT (SPECT) imaging with 
up to five scans of the thorax and pelvis were acquired at 
approximately 1, 4, 24, 48 and 72 h following administration 
of the radiopharmaceutical. SPECT images comprised 128 × 
128 voxels with a 4.67 mm3 voxel size. Further details of the 
patients and imaging acquisition and quantification can be 
found in.13,19,20 All patients provided written consent to partic-
ipate in the study, which was approved by the Royal Marsden 
NHS Foundation Trust and The Institute of Cancer Research 
Ethics Committee.
Extrapolation of the time–activity curve
The 186Re-HEDP activity was quantified based on phantom 
experiments as described previously.13 Activities were extrapo-
lated for other MRT treatments of bone metastases from prostate 
cancer, shown in Table 1: 450 MBq of 32P-Na₃PO₄ (sodium ortho-
phosphate),21, 22 150 MBq of 89Sr-dichloride,15, 23 37 MBq kg–1 
of 153Sm-EDTMP (ethylenediamine tetramethylene phospho-
nate),23 1100 MBq, of 166Ho-DOTMP  (1,4,7,10-tetraazacy-
clododecane-1,4,7,10-tetramethylene-phosphonate),24 37 
MBq kg–1 of 177Lu-EDTMP25, 26  and 3300 MBq of 188Re-HEDP 
(hydroxyethylidene diphosphonate).27, 28 Information on the 
biological half-lives of 153Sm-EDTPM and 177Lu-EDTMP in 
bone lesions is not presently available. However, given that 
the uptake mechanism of bisphosphonates is comparable, the 
biological half-lives were assumed to be the same as that of 
186Re-HEDP. A long biological half-life for 32P-Na₃PO₄ in bone 
lesions was assumed.22 Effective half-lives for 188Re-HEDP 
(bone lesions) and 166Ho-DOTMP (skeleton) were obtained 
from the literature.14, 24 Breen et al15 calculated a biological half-
life for 85Sr in bone lesions of 50 days and assumed to be the 
same for 89Sr, whilst other sources suggest a value of 90 days. An 
average of these two values has been used in this study for 89Sr. 
Differences in bone uptake as a percentage of the administered 
activity for the different radiopharmaceuticals were also taken 
into account.29 PSMA-targeting radiopharmaceuticals were not 
considered in this study due to their different uptake mecha-
nism as compared to 186Re-HEDP.
For any two given radiopharmaceuticals, the activity at any given 
time point t is calculated as:
 AD
(
t
)
= AD0 exp
(
−λDefft
)
 (1)
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Figure 1. Absorbed  dose voxel kernels as a function of the 
distance from the centre voxel for the radionuclides studied. 
Note the logarithmic scale of the vertical axis.
 AE
(
t
)
= AE0exp
(
−λEefft
)
  (2) 
where, in this study D and E refer to the delivered and extrapo-
lated treatment plans, respectively. The effective decay constants 
(λeff )  of the delivered and extrapolated treatment plans are 
defined as the sum of their respective biological (λbio) and phys-
ical (λphys) decay constants.
From the ratio of Equations (1) and (2) and solving for AE(t), the 
extrapolated activity at any given time point t is given by:
 AE
(
t
)
= A
E
0
AD0
AD
(
t
)
exp
[(
λDeff − λEeff
)
t
]
  (3)
Where AD(t)  is the activity for the delivered radiopharmaceu-
tical obtained from the quantified SPECT images, and AD0 and AE0  
are the administered activities for the delivered and extrapolated 
treatments plans respectively (Table  1). Equation 3 was used 
to extrapolate time–activity curves using available data on the 
biological retention and bone uptake for each radiopharmaceu-
tical from the quantified SPECT images of 186Re-HEDP.
Dosimetry
Following the Medical Internal Radiation Dosimetry pamphlet 
No. 17,30 the convolution dosimetry method was used, whereby 
the absorbed dose to any given target voxel (voxelt) is calculated 
by:
 Dvoxelt =
N∑
s=1
∼
Avoxels × S
(
voxelt ← voxels
)  (4) 
where 
∼
Avoxels is the voxelized cumulated activity distribution 
and  S
(
voxelt ← voxels
)
 is the absorbed dose S-value voxel 
kernel.
Voxelized cumulated activity distributions for 186Re-HEDP and 
the extrapolated treatments were obtained from the integra-
tion of the corresponding time–activity curves. Integration was 
performed between phases defined by the scan time points using 
an exponential or a trapezoidal fitting method subject to whether 
the activity between any two scan decreased or increased, 
respectively.
Absorbed dose voxel kernels for 32P, 89Sr, 153Sm, 166Ho, 177Lu, 
186Re and 188Re were generated using the EGS ++  class of the 
general purpose Monte Carlo code EGSnrc v.  4.31, 32 These 
were calculated in a voxelized geometry in a soft-tissue density 
medium with dimensions of 21 × 21 × 21 voxels and the same 
voxel size as the imaging data, 4.67 mm. The nuclear decay data 
were obtained from the Medical Internal Radiation Dosim-
etry RADTABS program.33 The developed software code has 
been previously verified by comparison with available voxel 
S-values.30, 34
The individual bone lesions were outlined from the calculated 
absorbed dose distributions on a HERMES workstation (Hermes 
Medical Solutions, Stockholm, Sweden) as part of a previous 
study13 and saved in eXtensible Markup Language format for 
further analysis. The convolution dosimetry and post-processing 
data analyses were carried out using MATLAB 2016b (The Math-
Works Inc., Natick, MA, US).
To reduce the effect of partial volume and the impact of the 
different spatial resolutions associated with each radionuclide, 
lesion peak absorbed doses were obtained by averaging the 
maximum voxel absorbed dose with the first nearest neighbour 
voxel values. Absorbed dose profiles were obtained for the deliv-
ered and extrapolated treatments, representing the distribution 
of bone lesion absorbed doses for the patient population. These 
were converted to cumulative dose volume histograms (cDVH) 
to study the spatial distribution of irradiated lesions across the 
patient cohort for each treatment. The patient population disease 
volume was defined as the sum of the metastatic tumour burdens 
for the 22 patients. The minimum absorbed dose to which 50% of 
the total volume was irradiated was calculated (D50).
Results
The dose voxel kernels for all the radionuclides studied are shown 
in Figure 1, and the S-values for the self-irradiation and the first 
nearest neighbour voxels are given in Table 2. The absorbed dose 
per decay rapidly decreases with the distance from the centre 
voxel, with a reduction of 89–99% in the first nearest voxel as 
compared to the self-irradiation voxel S-value. At distant voxels, 
higher S-values are observed for the radionuclides that also decay 
via γ-ray emission. The contribution to the lesion absorbed doses 
is negligible, as their contribution is four orders of magnitude 
lower.
A total of 379 bone lesions were identified in 22 patients. The 
absorbed dose profiles fitted to log-normal distributions deliv-
ered by 186Re-HEDP and extrapolated for the MRT treatment 
plans in Table  1   are shown in  Figure  2a and Figure  2b–g, 
respectively.
The median, minimum, maximum and D50-absorbed doses are 
shown in Table 3. A range of absorbeddoses could be delivered 
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Table 2. Voxel S-values for the self-irradiation and first nearest 
voxels for the radionuclides studied, where the number in the 
parentheses is the statistical uncertainty referred to the corre-
sponding last digits of the S-value
Radionuclide
S-value (Gy MBq –1h–1)
Self-irradiation Nearest neighbour
32P 2.1437 (5) 0.218209 (3)
89Sr 1.9573 (5) 0.1720 (2)
153Sm 1.3444 (4) 0.03031 (7)
166Ho 2.1929 (8) 0.2092 (3)
177Lu 0.7782 (3) 0.01066 (3)
186Re 1.4561 (5) 0.0655 (1)
188Re 2.2032 (8) 0.2477 (3)
Figure 2. Absorbed dose profiles delivered by 186Re-HEDP (a) and and extrapolated for typical administered activities of 
186Re-HEDP (b) 177Lu-EDTMP (c) 32P-Na3PO4 (d) 
153Sm-EDTMP (e) 166Ho-DOTMP (f) and 89Sr-dichloride (g) obtained from the 379 
bone lesions in the 22 patients. Note the three different ranges for the vertical axes: (a); (b-d); (e-g).
for typical empirically determined administered activities of 
the different treatments studied. If the same patient population 
was treated with 89Sr-dichloride, a 25% higher median lesion 
absorbed dose would have been delivered to the bone lesions. 
The other extrapolated treatments would have delivered lower 
lesion absorbed doses, ranging from −34% for 153Sm-EDTMP to 
−85% for 166Ho-DOTMP.
The absorbed dose profiles for the patient population calculated 
for each individual treatment were converted into cumulative 
dose-volume histograms, shown in Figure 3. The absorbed dose 
that irradiates 50% of the patient population disease volume 
ranged from 3.7 to 23.1 Gy for 166Ho-DOTMP and 89Sr-dichlo-
ride, respectively.
DisCussiOn
This study presents the methodology to calculate the 
absorbed dose that could be delivered for a given treatment using 
patient-specific sequential imaging of a delivered radiopharma-
ceutical. Its application to a cohort of patients with bone metas-
tases showed that a wide range of absorbed doses can potentially 
be delivered to the same patient cohort from typical empirically 
determined activities prescribed in a range of MRT treatments in 
patients with mCRPC.
Radiopharmaceuticals targeting bone metastases are incorpo-
rated into bone by different mechanisms. 89Sr or 223Ra belong 
to the alkaline earth metals in the second group of the periodic 
table and have similar chemical properties and interactions to 
those of calcium and are, therefore, directly incorporated into 
the bone matrix. Other radionuclides are chelated to phosphates, 
such as 153Sm-EDTMP, 166Ho-DOTMP, and 177Lu-EDTMP, 
186Re-HEDP and 188Re-HEDP which are incorporated into 
the hydroxyapatite. These bone-seeking radiopharmaceuticals 
can also be classified as volume-seekers, such as earth alkaline 
radionuclides with long half-lives that are initially deposited in 
the bone surface and slowly migrate through the bone mineral 
by chemical exchanges, and surface-seekers such as the chelated 
radionuclides. Radiolabelled PSMA-binding agents are a new 
class of treatments for mCRPC that target PSMA-expression of 
prostate cancer cells and, therefore, can deliver high radiation 
doses to the primary tumour, lymph node and bone lesions. All 
these radionuclides also emit γ-rays or bremsstrahlung radia-
tion, which allows imaging of the biokinetics and uptake distri-
bution with a γ-camera. Presently, dosimetry is not used to guide 
therapy and the prescribed activity is either fixed or adjusted by 
patient body weight.35 This is likely due to the challenges asso-
ciated with skeletal dosimetry, such as the variability of intraos-
seous trabecular distributions, the dynamic behaviour of bone 
marrow and the non-uniform distribution of uptake of bone-
seeking radionuclides. Therefore, absolute absorbed doses deliv-
ered to the bone lesions cannot be accurately calculated, mainly 
due to the limited image resolution and the highly heterogeneous 
uptake of the radiopharmaceutical. Nonetheless, relative dosim-
etry can still provide valuable information on treatment effi-
cacy when correlated with measures of treatment response and 
patient outcome.13
This study highlighted the differences in lesion absorbed 
doses that could be delivered to the same cohort of patients 
with mCRPC, if they were treated with other typical MRT 
administrations. Only 89Sr-dichloride would have deliv-
ered higher lesions (25%) doses than 186Re-HEDP. 32P-
Na3PO4, 153Sm-EDTMP, 166Ho-DOTMP, 177Lu-EDTMP and 
188Re-HEDP would have delivered 41, 32, 85, 20 and 64% 
lower absorbed doses for the typical administered activities, 
respectively.
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Table 3. Delivered (186Re-HEDP) and extrapolated median, minimum and maximum absorbed doses for the patient population and 
absorbed doses that cover 50% of the total disease volume of the population (D50)
Radiopharmaceutical Median [min–max] absorbed dose (Gy) Diff. from 186Re-HEDP (%) D50 (Gy)
32P-Na₃PO₄ 10.4 [2.3–55.4] −41 11.5
89Sr-dichloride 21.8 [4.5–117.6] 25 23.1
153Sm-EDTMP 12.2 [3.3–57.7] −32 13.0
166Ho-DOTMP 2.7 [0.6–11.8] −85 3.7
177Lu-EDTMP 14.0 [3.7–72.0] −20 14.8
186Re-HEDP 17.7 [3.9–87.5] − 18.4
188Re-HEDP 6.3 [1.5–27.1] −64 7.6
Figure 3. Cumulative absorbed dose volume histograms for 
the delivered and extrapolated treatment plans.
This study has some limitations. An assumption of uniform 
uptake distribution of the radiopharmaceuticals within the 
bone lesions was made due to the limited spatial resolution of 
present clinical imaging systems. This limitation on the spatial 
resolution justifies the assumption of uniform uptake in the bone 
lesion dosimetry studies performed to date.4, 5, 11–13, 18, 28, 36–39  
A previous study has shown that the uniformity assumption 
can underestimate the absorbed dose delivered to bone metas-
tases by a factor of up to 1.85 for lesions with a higher density.40 
The implications of this study are, however, of limited use in 
clinical practice, as it was based on simulations of absorbed 
dose distributions in a small number of biopsies from patients 
with mCRPC treated with 186Re-HEDP. Peak lesion absorbed 
doses were calculated to reduce the impact of partial volume 
effects due to the different spatial resolution of the various 
radionuclides. The methodology could be extended to include 
a point–spread function to correct the images to for the spatial 
resolution of the chosen radionuclide. Data on biological half-
lives and bone uptake for the different radiopharmaceuticals 
are presently limited and the methodology employed in their 
calculation is often not reported in the literature. Further image 
quantification studies with standardized protocols traceable 
to primary standards of activity41 are needed to determine 
the uptake and biological retention of radiopharmaceuticals. 
This would in turn improve the accuracy of the extrapolations 
presented in this study. The ultimate significance of the range 
of absorbeddoses that the patient cohort studied would have 
received cannot be established. The efficacy of these treat-
ments is likely dependant on the microscopic heterogeneous 
absorbed dose delivered to the tumorous tissue of the different 
radiopharmaceuticals and their associated toxicity profile. 
Therefore, a treatment that delivers a lower macroscopic mean 
lesion absorbed dose does not necessarily mean that it would 
be a more successful treatment. Correlations with treatment 
response and patient outcome are ultimately needed to under-
stand the targeting mechanisms of the different radiopharma-
ceuticals available.
The methodology presented here can be used to calculate 
absorbed doses delivered to any target by extrapolation of the 
corresponding time–activity curve and could potentially be used 
for extrapolating bone marrow or whole body absorbed doses. 
This would allow personalized treatment planning by maxi-
mizing the administered activity that would deliver an optimal 
therapeutic absorbed dose whilst limiting toxicity to the bone 
marrow. A range of MRT treatments could be planned using 
diagnostic imaging for different therapeutic radiopharmaceuti-
cals and a range of scan times, administered activities, uptakes 
and biological retentions functions. This would provide a range 
of treatment options to establish the optimal treatment. This 
methodology could be of particular importance for established 
and newly emerging theragnostic radiopharmaceuticals4, 42, 43 
and for repeated treatments like 223Ra-dichloride, where biodis-
tribution and pharmacokinetics have been shown to be largely 
consistent between administrations.44
COnClusiOn
The methodology to extrapolate the absorbed dose that would 
be delivered by any radiopharmaceutical using patient-specific 
imaging was presented and applied to a range of MRT treatments 
in patients with mCRPC. For the same patient cohort, a range 
of lesion absorbed doses was demonstrated for typical adminis-
trations protocols, whilst the impact of various assumptions was 
shown. This method has the potential to be used for personal-
ized treatment planning, in particular for emerging theragnostic 
radiopharmaceuticals.
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